-
Product Insights
Who Dat Field, United States
Who Dat upstream field is located in Central Planning Area, United States. The upstream field is owned by Deepwater Development Co LLC (49.75%); LLOG Exploration Offshore LLC (0%); LLOG Omega Holdings LLC (50.25%). It is operated by LLOG Exploration Offshore LLC. The project started its operations in 2011. Who Dat Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational...
-
Product Insights
WHO – Geneva WHO Headquarters Expansion – Geneva
Equip yourself with the essential tools needed to make informed and profitable decisions with our WHO - Geneva WHO Headquarters Expansion - Geneva report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
WHO – WHO Canal System Rehabilitation Project – Saramacca
Equip yourself with the essential tools needed to make informed and profitable decisions with our WHO - WHO Canal System Rehabilitation Project - Saramacca report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
WHO Dev – Columbus Mixed-Use Complex Development – Ohio
Equip yourself with the essential tools needed to make informed and profitable decisions with our WHO Dev - Columbus Mixed-Use Complex Development - Ohio report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Daratumumab + Hyaluronidase (Human Recombinant)) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Daratumumab + Hyaluronidase (Human Recombinant)) in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)Drug Details:Daratumumab and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Etanercept Biosimilar in Rheumatoid Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Etanercept Biosimilar in Rheumatoid ArthritisDrug Details:Etanercept (Rymti, Etera, Nepexto) is a dimeric fusion protein consisting of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Upadacitinib Er in Oligoarticular Idiopathic Juvenile Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib Er in Oligoarticular Idiopathic Juvenile Arthritis Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an antineoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Upadacitinib Er in Polyarticular Juvenile Idiopathic Arthritis (PJIA)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib Er in Polyarticular Juvenile Idiopathic Arthritis (PJIA) Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Upadacitinib Er in Hidradenitis Suppurativa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib Er in Hidradenitis Suppurativa Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an antineoplastic drug, acts...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Upadacitinib Er in Systemic Lupus Erythematosus
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib Er in Systemic Lupus Erythematosus Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an antineoplastic drug,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Upadacitinib Er in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib Er in Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Upadacitinib Er in Vitiligo
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Upadacitinib Er in Vitiligo Drug Details: Upadacitinib (Rinvoq, Rim-Voq) is an antineoplastic drug, acts as...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Medullary Thyroid Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Medullary Thyroid Cancer Drug Details: Pralsetinib (Gavreto) is an anticancer agent. It is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Molnupiravir in Respiratory Syncytial Virus (RSV) Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Molnupiravir in Respiratory Syncytial Virus (RSV) Infections Drug Details:Molnupiravir (Lagevrio, Lizuvira) is a potent ribonucleoside analog...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Solid Tumor Drug Details: Pralsetinib (Gavreto) is an anticancer agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pralsetinib in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pralsetinib in Pancreatic Cancer Drug Details: Pralsetinib (Gavreto) is an anticancer agent. It is formulated...
-
